147 related articles for article (PubMed ID: 16518076)
1. Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts.
Suzuki K; Takeyama S; Sakai Y; Yamada S; Shinoda H
J Pharmacol Sci; 2006 Mar; 100(3):189-94. PubMed ID: 16518076
[TBL] [Abstract][Full Text] [Related]
2. Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy.
Suzuki K; Takeyama S; Kikuchi T; Yamada S; Sodek J; Shinoda H
J Histochem Cytochem; 2005 Dec; 53(12):1525-37. PubMed ID: 16087705
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin posttranslational modifications, possibly phosphorylation, are required for in vitro bone resorption but not osteoclast adhesion.
Razzouk S; Brunn JC; Qin C; Tye CE; Goldberg HA; Butler WT
Bone; 2002 Jan; 30(1):40-7. PubMed ID: 11792563
[TBL] [Abstract][Full Text] [Related]
4. The integrin alpha(v)beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility.
Chellaiah MA; Hruska KA
Calcif Tissue Int; 2003 Mar; 72(3):197-205. PubMed ID: 12469249
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
6. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
7. Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures.
Nicolin V; Bareggi R; Baldini G; Bortul R; Martinelli B; Narducci P
Acta Histochem; 2007; 109(5):397-402. PubMed ID: 17574655
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
9. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
[TBL] [Abstract][Full Text] [Related]
10. Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors.
Vermeer JA; Jansen ID; Marthi M; Coxon FP; McKenna CE; Sun S; de Vries TJ; Everts V
Bone; 2013 Nov; 57(1):242-51. PubMed ID: 23962725
[TBL] [Abstract][Full Text] [Related]
11. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
12. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.
O'Brien EA; Williams JH; Marshall MJ
Biochem Biophys Res Commun; 2000 Aug; 274(2):281-90. PubMed ID: 10913332
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
15. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
[TBL] [Abstract][Full Text] [Related]
16. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
Woo JT; Kasai S; Stern PH; Nagai K
J Bone Miner Res; 2000 Apr; 15(4):650-62. PubMed ID: 10780857
[TBL] [Abstract][Full Text] [Related]
17. Regulatory mechanism of osteoclast activation.
Nakamura I; Rodan GA; Duong LT
J Electron Microsc (Tokyo); 2003; 52(6):527-33. PubMed ID: 14756240
[TBL] [Abstract][Full Text] [Related]
18. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.
Yu X; Schøller J; Foged NT
Bone; 1996 Oct; 19(4):339-45. PubMed ID: 8894139
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin antisense deoxyoligonucleotides inhibit bone resorption by mouse osteoclasts in vitro.
Tani-Ishii N; Tsunoda A; Umemoto T
J Periodontal Res; 1997 Aug; 32(6):480-6. PubMed ID: 9379315
[TBL] [Abstract][Full Text] [Related]
20. Palmatine attenuates osteoclast differentiation and function through inhibition of receptor activator of nuclear factor-κb ligand expression in osteoblast cells.
Lee JW; Mase N; Yonezawa T; Seo HJ; Jeon WB; Cha BY; Nagai K; Woo JT
Biol Pharm Bull; 2010; 33(10):1733-9. PubMed ID: 20930384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
